摘要
炎症性肠病(IBD)是慢性复发性肠道非特异性炎症。近年来,亚非国家IBD的发病率也呈上升趋势。儿童克罗恩病(CD)和溃疡性结肠炎(UC)的治疗反应个体差异很大。本文介绍氨基水杨酸类药物、糖皮质激素、免疫抑制药物、生物制剂及微生态制剂等在儿童IBD治疗中的应用,以及不同药物在诱导缓解和维持缓解中的作用,并探讨"下台阶"疗法在儿童IBD中的应用概念。
Inflammatory bowel disease （IBD） is a group of non-specific inflammatory conditions of the gastrointestinal tract that runs a chronic and relapsing course. The incidence is now being reported as on the increase in both Africa and Asia. In children the response to therapy could be highly variable. The purpose of this report is to discuss the role of 5-aminosalicylic acid, corticosteroids, immunomodulators, biologic agent and probiotics in the management of pediatric IBD and the medical options in induction therapy and maintenance of remission. The concept of ＂top-down＂ therapy in pediatric IBD is also discussed.
出处
《世界临床药物》
CAS
2009年第8期459-464,共6页
World Clinical Drug
关键词
炎症性肠病
克罗恩病
溃疡性结肠炎
儿童
inflammatory bowel disease
Crohn＇s disease
ulcerative colitis
children
